In addition to targeting EGFR, the inhibition of its downstream effectors, such as PI3K, AKT, and/or mTOR, exerted similar tumor-suppressing effects on HCC cells (Table 1). This evidence concerns the gene EGFR and hepatocellular carcinoma.